PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Context: Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. Objective: We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve stenosis and myocardial infarction. Design: We used two prospective cohort studies of the general population and one patient-based cohort. Setting: Cohort studies selected at random individuals of Danish descent. Participants: We studied 103 083 individuals from the Copenhagen General Population Study, the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. Main outcome measures: Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals. Results: Median (interquartile range) lipoprotein(a) levels were 10 (5–30) mg/dl for PCSK9 R46L noncarriers, 9 (4–32) mg/dl for heterozygotes, and 8 (4–42) mg/dl for homozygotes (trend P = .02). The corresponding values for LDL cholesterol levels were 124 (101–147) mg/dl, 104 (85–132) mg/dl, and 97 (85–128) mg/dl, respectively (trend P = 2 × 10−52). PCSK9 R46L carriers vs noncarriers had an age- and sex-adjusted odds ratio of 0.64 (95% confidence interval, 0.44–0.95) for aortic valve stenosis, 0.77 (0.65–0.92) for myocardial infarction, and 0.76 (0.64–0.89) for aortic valve stenosis or myocardial infarction. Conclusions: PCSK9 R46L carriers have lower levels of lipoprotein(a) and LDL cholesterol as well as reduced risk of aortic valve stenosis and myocardial infarction. This indirectly suggests that PCSK9 inhibitors may have a role in patients with aortic valve stenosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 5×
“Specifically, the PCSK9 R46L loss-of-function mutation has been associated with lower levels of LDL cholesterol and with reduced risk of ischemic heart disease and MI (11, 13, 14).”
BackgroundResultInfluentialEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 2×
“However, PCSK9 inhibitor treatment has also been shown to lower lipoprotein(a) (15, 16).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 2×
“The Copenhagen City Heart Study is a prospective study of the general population initiated in 1976–1978 with follow-up examinations in 1981–1983, 1991–1994, and 2001–2003 (18).”
BackgroundSelf-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 2×
“Recently, however, several other risk factors similar to those for coronary artery disease have emerged and include smoking, high blood pressure, high cholesterol, diabetes, and male sex (25).”
BackgroundLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“A limitation of our study is that we included only white individuals of Danish descent and this may limit the applicability to other ethnicities, especially because lipoprotein(a) levels differ among different ethnic groups (6, 7, 27).”
BackgroundSelf-citation(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Research works printed but not linked: 1
- Utermann, 2001, Lipoprotein(a), 2753
Cited by
Items 101–138 of 138
Genetics of Calcific Aortic Stenosis: A Systematic Review
Vassiliou, V. S., Johnson, N. J., Langlands, K., & Tsampasian, V. (2024) · Genes · doi:10.3390/genes15101309 · Cited by 5
“Similar results were also obtained by Perrot et al. [27], who identified an OR = 0.80 (CI = 0.70–0.91, p = − 0.001) for the same variant.”
ResultInfluentialSalinger, T., Hu, K., Liu, D., Taleh, S., Herrmann, S., Oder, D., Gensler, D., Müntze, J., Ertl, G., Lorenz, K., et al. (2018) · Cardiology Research and Practice · doi:10.1155/2018/3713897 · Cited by 5
Unraveling the Link Between Aortic Stenosis and Atherosclerosis: What Have We Learned?
Cinezan, C., Rus, C. B., & Ilias, I. T. (2025) · Medicina · doi:10.3390/medicina61081375 · Cited by 4
“Langsted et al. [110] showed that PCSK9 R46 L carriers have lower levels of Lp(a) and LDL cholesterol and also a reduced risk of myocardial infarction and of aortic stenosis, suggesting that PCSK9 inhibitors may have a role in patients with aortic stenosis.”
SU, H., Guo, X., Li, Q., Yuan, X., Wu, X., Zhao, Z., Kan, Y., Yang, Y., Fu, Z., Qi, Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1744830 · Cited by 4
“Elevated PCSK9 and Lp(a) are major independent genetic risk factors for aortic stenosis (77).”
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 4
Nasso, G., Vignaroli, W., Amodeo, V., Bartolomucci, F., Larosa, C., Contegiacomo, G., Demola, M. A., Girasoli, C., Valenzano, A., Fiore, F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102987 · Cited by 4
“In these studies, subjects who have lifelong LDL-C levels of ~15 mg/dL are also well, without apparent health, learning, or reproductive concerns [7,44–48].”
BackgroundEncouraging a move toward precision geromedicine
Ferrucci, L., Donegà, S., Maier, A. B., & Kroemer, G. (2026) · Geromedicine · doi:10.70401/geromedicine.2026.0020 · Cited by 4
“…associate with lower triglycerides and reduced cardiometabolic risk [33] , whereas proprotein convertase subtilisin/kexin type 9 (PCSK9) loss-of-function variants (for example R46L) reduce low-density lipoprotein (LDL) cholesterol and are associated with lower cardiovascular risk [34,35] .”
Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography
Oostveen, R. F., Kaiser, Y., Stroes, E. S. G., & Verberne, H. J. (2022) · Pharmaceuticals · doi:10.3390/ph15070812 · Cited by 3
“This is because the PCSK9 R46L loss-of-function mutations, which cause reduced exposure to these lipoproteins, are associated with a reduced risk of aortic valve stenosis [7].”
BackgroundResidual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
Hou, Y., Zhao, J., Xu, W., Chen, L., Yang, J., Wang, Z., & Si, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34089 · Cited by 2
“Similarly, loss-of-function mutations of PCSK9 R46L in humans have also been found to mitigate the risk of CAVS [33].”
BackgroundLusiki, Z., Blom, D. J., Soko, N. D., Malema, S., Jones, E. S. W., Rayner, B. L., Blackburn, J. M., Sinxadi, P., Dandara, M. T. L., & Dandara, C. (2024) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0122 · Cited by 2
PCSK9 genetic variants, carotid atherosclerosis and vascular remodelling
Coggi, D., Ward, J., Gigante, B., Gigante, B., Lyall, D. M., Frigerio, B., Ravani, A., Sansaro, D., Ferri, N., Lupo, M. G., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003348 · Cited by 1
Lipoprotein(a) in familial hypercholesterolemia
Jaafar, A. K., Bourane, S., Lambert, G. C., & Chemello, K. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001032 · Cited by 1
Courtney, W., Walker, J. A., Dorai-Raj, A., Arnous, S., O’Connor, C. T., Playford, D. A., Ihdayhid, A. R., Schultz, C. J., Hillis, G. S., & Kiernan, T. J. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2652411 · Cited by 1
Rodríguez‐Nóvoa, S., Hernández, P. M., Mayoral, I. H., Herranz, A., Roca, N. R., Alvarez, A. C., Onis, N. G., Alcorta, M. D., & Jiménez, C. R. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100607 · Cited by 1
“PCSK9 p. (Arg46Leu) variant is a well-established LOF variant that has been consistently associated with lower LDL-cholesterol concentrations, cardiovascular disease and reduced circulating PCSK9 levels [17] [37] [38].”
Lipoprotein(a)—It Is Risky, but What Do We Do About It?
Després, A.-A., & Arsenault, B. J. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0592-7 · Cited by 1
Statine: Nebenwirkungen – alternative Therapieoptionen
Makhmudova, U., & Weingärtner, O. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00669-w · Cited by 1
Perrot, N., Moschetta, D., Boekholdt, S. M., Valerio, V., Martinsson, A., Capoulade, R., Mass, E., Clavel, M.-A. A., Wareham, N. J., Dina, C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/560458
Medical Treatment for Aortic Valve Disease
Huseynov, A., Behnes, M., & Akın, İ. (2019) · Springer eBooks · doi:10.1007/978-3-030-05912-5_43
Update on genetics and molecular biology
Santos, R. D., & Chacra, A. P. M. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000633
Elektronische Koordinaten als Dienstleistung des E-Business.
Lindstädt, H., & Wiegand, M. (2002)
Updates on genetics and molecular biology
Rocha, V. Z., & Santos, R. D. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000772
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013 · Cited by 1
Reiner, Ž., Miličić, D., Rogić, D., Manola, Š., Ružić, A., Canecki-Vražić, S., Kristić, I., Zulle, B.-L., Đerek, L., Šerić, V., et al. (2024) · Liječnički vjesnik · doi:10.26800/lv-146-1-2-7
Additional file 2 of Myeloid CCN3 protects against aortic valve calcification
Tu, P., Xu, Q., Zhou, X., Villa-Roel, N., Kumar, S., Dong, N., Jo, H., Ou, C., & Lin, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22610938
Zulkapli, R., Muid, S. A., Wang, S. M., Radzi, A. B. M., Ibrahim, K. S., Yusof, M. Y. P. M., & Nawawi, H. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-36716-7
Huang, K., & Ren, J. P. (2026) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2025.33
Mudla, A., Quintana, D. D., Atallah, C. F., Savoy, L. R., Leu, A. I., Dam, T., Acharya, G., Rajappan, K., & Chivukula, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.20.713290
Rodríguez‐Nóvoa, S., Hernández, P. M., Mayoral, I. H., Herranz, A., Roca, N. R., Alvarez, A. C., Onis, N. G., Alcorta, M. D., & Jiménez, C. R. (2026) · medRxiv · doi:10.64898/2026.03.26.26348145
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff · Cited by 1
Effets de PCSK9 sur l'allergie
Lorant, V. (2023) · theses.fr (ABES) · doi:10.70675/167b7030z0433z4ddaz899bz309566978a8a · Cited by 1
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsarac25dcb0d
Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review)
Tang, L., Yao, S., Zhu, Y., he, Z., Ramos‐Molina, B., & Xu, Y. (2026) · Oncology Letters · doi:10.3892/ol.2026.15767
“Among the numerous PCSK9 variants identified to date, the most prevalent LOF variant is R46L, reported in >100,000 individuals across diverse ethnic groups, including British (16), Italian (17), Swedish (18), Canadian (19), Danish (20) and Spanish (21) populations.”
Aortic valve stenosis in 2026: from emerging mechanisms to clinical drug development
Zheng, K. H., Gaillard, É., Kroon, J., Stroes, E. S. G., & Boekholdt, S. M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121865
Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies
Tokgözoğlu, L. S., & Kayıkçıoğlu, M. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.101
“67 In a large drug-target Mendelian randomisation study by Ciofani et al., genetically proxied PCSK9 inhibition was associated with a substantially lower risk of AS (OR 0.61; 95% CI [0.52–0.72]).”
InfluentialNovel pharmacological targets for the treatment of aortic stenosis
Anchouche, K., Small, A. M., & Thanassoulis, G. (2026) · European Heart Journal - Valvular and Structural Heart Disease · doi:10.1093/ehjvshd/xwag069
Anlaş, Ö., Albuz, B., & Bulut, F. D. (2026) · Pediatrics International · doi:10.1111/ped.70594
Metadata
- Authors
- Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R.
- Affiliations
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- The Copenhagen General Population Study (A.L., B.G.N., M.B., A.T.-H., P.R.K.), Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
- Corresponding author
- Kamstrup, Pia R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-24
- Volume
- 101
- Issue
- 9
- Pages
- 3281-3287
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2404696858
- Cited by
- 136
- References
- 33
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 8 · 2016: 1
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Sanofi
- Fresenius Medical Care North America
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, loss-of-function mutations, lipoprotein(a), LDL cholesterol, aortic stenosis, myocardial infarction, PCSK9 inhibitors, genetic association, cardiovascular risk, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease prevention, Danish population, Copenhagen General Population Study, Copenhagen City Heart Study
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Genotype, Heterozygote, Humans, Cholesterol, LDL, Male, Middle Aged, Mutation, Myocardial Infarction, Prognosis, Prospective Studies, Risk Factors, Biomarkers, Lipoprotein(a), Genetic Predisposition to Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.